Overview

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
It is a single-arm, open-label, multicenter, phase I trial,aiming at exploring the MTD and RP2D of Linperlisib combination with Camrelizumab in treating patients with advanced solid tumor,observing the preliminary efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai YingLi Pharmaceutical Co. Ltd.